Yi-Chao Han

The Adjuvant-Phase Dilemma After Neoadjuvant Chemoimmunotherapy in Resectable NSCLC: Evidence and Response-Guided Strategies

Simple Summary Perioperative immunotherapy, which includes treatment before and after surgery, has improved outcomes for some patients with resectable non-small cell lung cancer. However, current clinical trials usually test the entire treatment plan rather than the separate value of continuing immunotherapy after surg...

Recent Advances and Future Challenges of Bispecific Antibodies in Lung Cancer.

Bispecific antibodies (BsAbs) integrate two binding specificities to coordinate antitumor mechanisms that cannot be readily achieved with conventional monospecific antibodies. In lung cancer, these agents encompass four principal strategies: dual targeting of tumor-associated receptors, immune-cell redirection, simulta...

Tumor-intrinsic NSUN2 orchestrates immunosuppression in lung adenocarcinoma via the m5C-HDAC8-CCL5 axis

Findings identify NSUN2 as a critical orchestrator of T-cell exclusion in LUAD and serves as both a candidate predictive biomarker for ICI failure and a promising druggable target for immunotherapy resistance.

Targeting the FOXP3—T-bet interaction to restore Treg stability in IFN-γ—driven autoimmunity 2254306

Regulatory T cells (Tregs) maintain immune homeostasis through FOXP3-centered transcriptional complexes that tightly control lineage stability and suppressive function. However, how specific FOXP3 mutations disturb this complex and drive pathogenic Treg reprogramming in IPEX syndrome remains unclear. We identifie...

Targeting the FOXP3–T-bet interaction to restore Treg stability in IFN-γ–driven autoimmunity